Hematology and clinical operations
SELLAS REGAL: AML Survival Results and the Work Behind Follow-Up
What SELLAS’s Phase 3 REGAL topline means for AML maintenance, survival evidence, clinical trial follow-up and oncology monitoring responsibilities.
By Lampgen Clinical Research

5 min read · estimated
What the source reported
SELLAS reports median overall survival of 24.0 versus 14.7 months (hazard ratio 0.59; p=0.035; n=126), meeting REGAL’s primary endpoint at 80 deaths. Treatment-related events were mostly mild or moderate. GPS remains investigational. [1]
Keep the population and comparator attached to the headline
REGAL is a randomized, open-label maintenance study in AML after second or later remission, including incomplete platelet recovery, for patients unable to undergo allogeneic transplant at entry. Its comparator is investigator-selected best available treatment. [2, 3]
That comparator can include observation or specified drug regimens. A complete assessment should examine what patients actually received, alongside subsequent therapies and follow-up. [3] The result cannot establish superiority to every individual AML treatment.
The hazard ratio describes relative event timing over follow-up. It does not mean a 41-percentage-point survival gain. The difference between median survival estimates is 9.3 months; individual outcomes vary. Regulatory decisions require the complete evidence.
Why the treatment strategy matters
Galinpepimut-S is an off-the-shelf WT1-directed peptide immunotherapy designed to stimulate T-cell responses against residual cancer cells. [4] The development question is whether that immune strategy can improve outcomes after remission has been achieved.
Lampgen’s interpretation is that a credible maintenance option in this setting could change the work of future study planning: investigators would need to consider the evolving treatment landscape, relevant comparators and what participation would ask of patients. Those consequences depend on detailed review and any eventual approval.
The announcement does not establish reduced clinic burden or improved quality of life. Those questions need appropriate patient-experience and resource-use evidence.
A survival endpoint needs continuity after dosing stops
The REGAL study description includes long-term follow-up after the end of treatment. [3] In oncology endpoint guidance, FDA discusses the importance of survival follow-up and the potential effects of subsequent therapy. [5]
For a similar protocol, the operational task is to establish who owns each permitted contact and record request when treatment stops, care transfers or a participant changes contact details. The plan should follow the protocol, consent and applicable requirements.
A monitoring report can show that a site answered a query while leaving the next follow-up contact without an owner. Study-level review should therefore ask whether the process can keep working after the immediate action is closed.
What an oncology CRA should be able to reconstruct
1. Establish the patient’s current study status. Reconcile treatment discontinuation, ongoing follow-up and any withdrawal of permission. Those statuses should not be treated as interchangeable.
2. Trace the vital-status record. Identify the date, accepted source and any unresolved discrepancy. Use authorized records and contact routes; do not infer a death or loss to follow-up from a missed visit.
3. Escalate unresolved handoffs. Show who requested the missing information, who can resolve it and when the agreed process calls for escalation.
4. Verify the next cycle. Review whether subsequent records demonstrate the intended change. A closed action is evidence of an administrative step; continued completeness is what the study needs.
These are proposed responsibilities for comparable studies, not findings from an audit of REGAL. Investigators retain medical decisions, sponsors retain oversight, and medical and statistical teams determine the clinical and analytical interpretation.
Use SIGNAL to investigate a recurring gap
Consider a fictional example: more than one site has overdue follow-up after participants return to community care. A study manager using SIGNAL™ would investigate the handoff, gauge whether the pattern recurs, name the risk and assign action through the sponsor’s process.
Useful proposed review measures include overdue contacts, age of unresolved records and follow-up completeness by site and treatment arm. The statistical team should assess censoring and potential analytical consequences. Operational teams should not invent a universal threshold or repair the dataset by assumption.
After a process change, review the next follow-up cycle. Check whether authorized records arrive and responsibilities remain clear. The point is to learn whether the handoff improved.
Patient support belongs in that review. Ask whether travel, language, caregiving or fragmented care affects the ability to stay connected. REGAL’s topline announcement does not establish a disparity; the proposed checks help a team identify one if it arises.
What the full readout still needs to clarify
Detailed analyses remain pending. [1] A complete assessment should address the hazard-ratio confidence interval, survival curves and numbers at risk, duration and completeness of follow-up, control-arm composition, subsequent therapies and adverse-event rates.
The open-label design and modest sample require careful interpretation, especially for subgroup claims. Overall survival has direct clinical meaning, while care after randomization and incomplete follow-up can still affect how an observed difference is understood. [5]
This commentary uses public disclosures and is not an independent audit of REGAL. The operational analysis applies the development to responsibilities that sponsors and CROs can define in their own studies.
What this means for trial teams
For sponsors and CROs, the practical staffing question is whether the assigned oncology CRA and study-management roles cover follow-up reconciliation, cross-team escalation and verification after action. FDA’s ICH E6(R3) guidance emphasizes proportionate quality management and clear sponsor and investigator responsibilities. [6]
Lampgen Clinical Research scopes oncology clinical-operations support around those defined responsibilities. The appropriate discussion starts with the actual protocol, monitoring plan, current workload and decision ownership. [7]
Analysis by Tommy Lampley, Jr., M.S., Founder, Lampgen Clinical Research. Published November 17, 2026. The accompanying visual is a conceptual illustration, not a study workflow, participant or treatment outcome.
Sources
- SELLAS — original REGAL Phase 3 topline disclosure, November 17, 2026
- ClinicalTrials.gov — REGAL, NCT04229979
- UCLA trial listing — REGAL design, eligibility and follow-up; older planned enrollment differs from actual topline enrollment
- SELLAS — galinpepimut-S scientific rationale
- FDA — Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
- FDA — ICH E6(R3) Good Clinical Practice
- Lampgen — oncology CRA staffing
- STAT, Adam Feuerstein — November 17 reporting; accessible introduction reviewed, full article requires STAT+
- Related Tommy Lampley analysis — survival after AML remission
- Related Lampgen insight — overall survival and long-term follow-up